EUVIMEDScopri EUVIMED
Systematische ÜbersichtOpen access · CC BY-NC-ND 4.0

Blood Pressure–Lowering Effects of Aldosterone Synthase Inhibitors—A Systematic Review

Anders Almskou Rasmussen, Ketil Lehm Nordestgaard, Ulf Simonsen iD, Niels Henrik Buus iD

Basic & Clinical Pharmacology & Toxicology · 2025

DOI: 10.1111/bcpt.70080 ↗

At a glance

Systematische Übersicht in Basic & Clinical Pharmacology & Toxicology, 2025. Written by Anders Almskou Rasmussen and 3 co-authors. Institution: Department of Biomedicine, HEALTH, Aarhus University, Aarhus, Denmark. Major MEDLINE topics: Hypertension, Cytochrome P-450 CYP11B2, Antihypertensive Agents, Blood Pressure. Cited 16 times so far (Crossref); 51 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIGMS NIH HHS.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Excess aldosterone production contributes to the development of hypertension and results in fibrosis with dysfunction of the heart, vasculature and kidneys. Consequently, new agents have been developed to reduce endogenous aldosterone synthesis. The primary objective of this systematic review is to describe the BP‐lowering effects of aldosterone synthase inhibitors (ASIs) in hypertensive patients and, secondly, to describe their potential renal protective effects and possible influence on cortisol production and plasma potassium. We searched PubMed, Embase and ClinicalTrials.gov and included randomized controlled and clinical trials according to PICO using the review tool Covidence. Thirteen studies were included and all demonstrated BP reduction through ASI treatment. Among patients with apparent resistant hypertension, the placebo‐corrected reductions in seated systolic BP were 11.0 mmHg for baxdrostat and 9.6 mmHg for lorundrostat. A significant suppression of cortisol production was found for LCI699 (osilodrostat) but not for baxdrostat, lorundrostat, BI 690517 (vicadrostat) or dexfadrostat. Studies on BI 690517 showed a reduction in urine–albumin–creatinine ratio, indicating renal protection. ASIs may increase potassium levels. We conclude that ASIs have promising BP‐lowering effects with very limited effects on cortisol production and offer reno‐protective effects in chronic kidney disease. Studies on hypertensive target organ damage and cardiovascular outcomes are, however, lacking.

Subjects

MeSH terms (MEDLINE)

HypertensionCytochrome P-450 CYP11B2Antihypertensive AgentsBlood PressureEnzyme InhibitorsHumansHydrocortisonePotassiumRandomized Controlled Trials as TopicAldosteroneKidneyRenal Insufficiency, Chronic

Author keywords

albuminuriaaldosterone synthase inhibitionblood pressurechronic kidney diseasecortisolhyperkalaemiahypertension

Substances

Cytochrome P-450 CYP11B2Antihypertensive AgentsHydrocortisonePotassiumAldosteroneEnzyme Inhibitors

Authors and institutions

  • Department of Biomedicine, HEALTH, Aarhus University, Aarhus, Denmark.
  • Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark.

ORCID profiles: Ulf Simonsen, Niels Henrik Buus

Funding

  • NIGMS NIH HHS

Cite

APA

Rasmussen, A. A., Nordestgaard, K. L., Simonsen, U., & Buus, N. H. (2025). Blood Pressure–Lowering Effects of Aldosterone Synthase Inhibitors—A Systematic Review. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70080

Vancouver

Rasmussen AA, Nordestgaard KL, Simonsen U, Buus NH. Blood Pressure–Lowering Effects of Aldosterone Synthase Inhibitors—A Systematic Review. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70080

BibTeX
@article{Rasmussen2025,
  author = {Rasmussen, Anders Almskou and Nordestgaard, Ketil Lehm and Simonsen, Ulf and Buus, Niels Henrik},
  title = {Blood Pressure–Lowering Effects of Aldosterone Synthase Inhibitors—A Systematic Review},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  doi = {10.1111/bcpt.70080}
}
Start for free →